Bipartisan INSULIN Act Seeks $35 Cap for Privately Insured
A bipartisan group of U.S. senators has introduced the INSULIN Act, a federal bill that would cap out-of-pocket insulin costs at $35 per month for Americans with private insurance and create a pilot program in 10 states to offer more affordable insulin to uninsured patients. Sponsored by Sens. Jeanne Shaheen (D‑N.H.), Raphael Warnock (D‑Ga.), Susan Collins (R‑Maine) and John Kennedy (R‑La.), the measure aims to extend protections similar to the Inflation Reduction Act’s $35 Medicare cap to working‑age diabetics who currently face widely varying costs. The bill comes as about 8.1 million Americans use insulin, including more than 2 million with Type 1 diabetes who cannot live without it, and as half of states have passed their own caps that still leave out roughly 57% of privately insured people in self‑funded plans. Major manufacturers Eli Lilly, Sanofi and Novo Nordisk have announced list‑price cuts and co‑pay caps, but advocates and clinicians say many patients still struggle to navigate complex discount programs or lack coverage altogether. The proposal faces fiscal and political hurdles in a Republican‑controlled Congress, yet is being touted as one of the few plausible bipartisan wins on health care costs in a year when voters are fuming about medical bills and drug prices.
📌 Key Facts
- The INSULIN Act would cap insulin out-of-pocket costs at $35 per month for Americans with private insurance plans.
- The bill is sponsored by Sens. Jeanne Shaheen, Raphael Warnock, Susan Collins and John Kennedy and was introduced in late March 2026.
- The legislation would launch a pilot program in 10 states to provide more affordable insulin options to uninsured Americans.
- About 8.1 million people in the U.S. use insulin, including over 2 million with Type 1 diabetes who are dependent on the drug to survive.
- Roughly 57% of Americans with private insurance are in self-insured plans that state-level insulin co‑pay caps do not cover.
📊 Relevant Data
In 2023, the prevalence of diagnosed diabetes among U.S. adults was 12.2% for non-Hispanic Black adults, compared to 7.1% for non-Hispanic White adults, 11.8% for Hispanic adults, 9.7% for non-Hispanic Asian adults, and 15.7% for American Indian or Alaska Native adults. Non-Hispanic Black adults make up about 13.6% of the U.S. population, while non-Hispanic White adults comprise about 59%.
Studies indicate that racial disparities in diabetes prevalence in the U.S. are influenced by a combination of genetic and social factors, with higher rates among Black Americans potentially linked to both genetic predispositions and socioeconomic elements.
Is Diabetes More Common in Black Americans? — Healthgrades
In a 2023 study, insulin pump use among youth with type 1 diabetes was 67% for non-Hispanic White individuals, compared to 41% for Hispanic, 29% for Black, and 46% for other racial and ethnic groups, indicating disparities in access to advanced diabetes management technology.
Black Medicare enrollees would have benefited significantly from insulin cost caps, with about 158,000 projected to gain from the policy if implemented in 2020, reflecting higher diabetes burdens in this group.
Projected Impacts for Black Medicare Enrollees — ASPE (Assistant Secretary for Planning and Evaluation)
📰 Source Timeline (1)
Follow how coverage of this story developed over time